Associated Papers
The prognostic impact of CDKN2A/B hemizygous deletions in meningioma.
Ippen FM et al.
Neuro-oncology, 2026
Analytical Validation and Clinical Sensitivity of the Belay Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test-An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies.
Khurana S et al.
Cancers, 2026
Expanding the paradigm of the recurrent mosaic SMO c.1234C>T variant: a patient with a linear blaschkoid congenital lesion with multiple basal cell carcinomas.
Tan L et al.
Clinical and Experimental Dermatology, 2025
Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.
Papaccio F et al.
International Journal of Molecular Sciences, 2025
Does Basal Cell Carcinoma Arise from a Precursor Lesion?
Wong SY et al.
The Journal of Investigative Dermatology, 2025
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Tsao AS et al.
Jco Precision Oncology, 2025
Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.
Kim YA et al.
International Journal of Molecular Sciences, 2025
Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients.
You Z et al.
Oral Diseases, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Multimorbidity Through the Lens of the Eye: Pathogenic Variants for Multiple Systemic Disorders Found in an Autosomal Dominant Congenital Cataract Cohort.
Berry V et al.
Genes, 2025
European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.
Sahm F et al.
Neuro-oncology, 2025
Novel germline and somatic variants in familial and sporadic meningioma genes.
Bencheikh BOA et al.
Npj Genomic Medicine, 2025
Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study.
Barbieux S et al.
Pathology, 2025
Molecular and histopathological landscape of 131 meningiomas: a retrospective institutional study with insights from cIMPACT-NOW.
Ali RH et al.
Frontiers in Oncology, 2025
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
POLR2A Mutation is a Poor Prognostic Marker of Cerebellopontine Angle Meningioma.
Okano A et al.
Neurosurgery, 2024
A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1.
Graillon T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Integrative genomic analysis reveals cancer-associated mutations in patients with ophthalmic tumors.
Zhu F et al.
The Journal of International Medical Research, 2024
Molecular pathogenesis of ameloblastoma.
Marín-Márquez C et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
Symes E et al.
Histopathology, 2024
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.
Youngblood MW et al.
Nature Communications, 2023
The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review.
Malakar A et al.
Cureus, 2023
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y et al.
Head and Neck Pathology, 2023
Hedgehog pathway mutations are involved in the pathogenesis of plaque-type "trichoblastoma": A report of two cases.
Giang J et al.
Journal of Cutaneous Pathology, 2023
Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease.
Mishra-Gorur K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Genetic heterogeneity and enrichment of variants in DNA-repair genes in ameloblastoma.
Awotoye W et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2023
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P et al.
Cancers, 2023
DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
Singh J et al.
Journal of Neuro-oncology, 2023
Genomic Landscape of Meningiomas.
Wang JZ et al.
Advances in Experimental Medicine and Biology, 2023
Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients.
Aran V et al.
Frontiers in Neurology, 2023
Segmental basaloid follicular hamartomas derive from a post-zygotic SMO p.L412F pathogenic variant and express hair follicle development-related proteins in a pattern that distinguish them from basal cell carcinomas.
Atzmony L et al.
American Journal of Medical Genetics. Part A, 2022
New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
Nguyen J et al.
Journal of Dental Research, 2022
Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.
Hoashi T et al.
International Journal of Molecular Sciences, 2022
Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer.
Nicheperovich A et al.
Journal of Personalized Medicine, 2022
Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer.
Suchors C et al.
Cells, 2022
Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres.
Bonacina R et al.
Journal of Clinical Pathology, 2022
Molecular diagnostics in odontogenic tumors.
Buettner R et al.
Pathologie (heidelberg, Germany), 2022
NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas.
Sakai Y et al.
Cancers, 2022
Genetic Study of BRAF V600E and SMO L412F Mutations in Japanese Patients with Ameloblastoma.
Kokubun K et al.
International Journal of Surgical Pathology, 2022
Cancer stem cells, not bulk tumor cells, determine mechanisms of resistance to SMO inhibitors.
George J et al.
Cancer Research Communications, 2022